Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06855706 · ClinicalTrials.gov registry record · NA

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

A NA study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, sponsored by Roswell Park Cancer Institute.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06855706 is a NA study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 120 participants, roughly in line with the 121-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06855706, a NA study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial cancer that is newly diagnosed. Physical activity is a modifiable risk factor for the prevention and treatment of many diseases. In fact, increased levels of physical activity have been shown to decrease the risk of some cancers as well as increase overall survival in some cancers. Currently, standard of care guidelines include participation in at least 150 minutes of moderate exercise weekly. An automated personalized physical activity intervention may increase physical activity, enhance quality of life, and improve physical function and daily living activities compared to standard recommendations in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer. This trial also evaluates the impact of physical activity on the gut microbiome and immune function. The microbiome is the collection of tiny organisms, like bacteria, that live in and on the body, especially places like the gut. These microorganisms play an important role in health. Information gathered from this study may help understand how the gut microbiome and physical activity influences the immune system in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Exercise Intervention
  • OTHER Best Practice
  • BEHAVIORAL Behavioral Intervention
  • OTHER Electronic Health Record Review

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-06-04
Est. Completion 2028-04-30
Phase NA

Sponsor

Roswell Park Cancer Institute

365 total trials

What the Registry Record Tells You About NCT06855706

The ClinicalTrials.gov registry entry for NCT06855706 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 121-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06855706 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06855706 about?

NCT06855706 is a clinical study titled "An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study". This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial can...

What is the current status of trial NCT06855706?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-06-04. Estimated completion is 2028-04-30.

What conditions does trial NCT06855706 study?

This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Endometrial Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage III Ovarian Cancer AJCC v8.

What interventions are being tested in trial NCT06855706?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Exercise Intervention (OTHER), Best Practice (OTHER), Behavioral Intervention (BEHAVIORAL), Electronic Health Record Review (OTHER).

Who is sponsoring clinical trial NCT06855706?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06855706 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Recurrent Ovarian Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.